Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda, Amgen Sign Mega Japanese Deal

This article was originally published in PharmAsia News

Executive Summary

Amgen and Takeda Pharmaceutical have signed a deal worth up to $1.18 billion that provides Takeda with Japanese rights to up to 12 new biopharmaceuticals from Amgen's pipeline. In addition, Takeda will acquire Amgen's Japanese unit and receive worldwide rights to Amgen's experimental cancer therapy motesanib diphosphate. In return, Amgen will retain Japanese co-promotion rights and receive at least 10 percent royalties on sales in Japan. Takeda will pay Amgen $200 million up front and as much as $702 million in milestones for the 12 compounds, as well as $100 million up front for motesanib diphosphate and up to $175 million in milestones. The deal comes as Takeda looks to shore up its pipeline prior to patent expiration of best-selling diabetes drug Actos, and as Amgen struggles to regain its footing in the wake of safety concerns over its anemia franchise. (Click here for more

You may also be interested in...

Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings

Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.

SynOx Seeks Solution For TGCT With Roche Antibody

The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.

Oxford/AstraZeneca Vaccine Shows 70% Efficacy As Company Prepares Approval Filings

Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts